These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9858850)

  • 21. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy.
    Nejat RJ; Rashid HH; Bagiella E; Katz AE; Benson MC
    J Urol; 2000 Dec; 164(6):1891-4. PubMed ID: 11061874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression.
    Lane TM; Ansell W; Farrugia D; Wilson P; Williams G; Chinegwundoh F; Philp T; Hines J; Oliver RT
    Urol Int; 2004; 73(2):117-22. PubMed ID: 15331894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer: finasteride extends PSA doubling time during intermittent hormone therapy.
    Locke JA; Bruchovsky N
    Can J Urol; 2010 Jun; 17(3):5162-9. PubMed ID: 20566007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Radical prostatectomy as monotherapy for locally advanced prostate cancer (T3a): 12 years follow-up].
    Isorna Martínez de la Riva S; Belón López-Tomasety J; Marrero Domínguez R; Alvarez Cruz E; Santamaría Blanco P
    Arch Esp Urol; 2004 Sep; 57(7):679-92. PubMed ID: 15536949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
    Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K
    Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer.
    Shaw G; Oliver RT
    Surg Oncol; 2009 Sep; 18(3):275-82. PubMed ID: 19269165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight.
    Tunn U
    BJU Int; 2007 Jan; 99 Suppl 1():19-22; discussion 23-4. PubMed ID: 17229164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
    Gleave M; Klotz L; Taneja SS
    Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intermittent androgen suppression for prostate cancer: rationale and clinical experience.
    Gleave M; Goldenberg SL; Bruchovsky N; Rennie P
    Prostate Cancer Prostatic Dis; 1998 Dec; 1(6):289-296. PubMed ID: 12496869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival benefit for early hormone ablation in biochemically recurrent prostate cancer.
    Tenenholz TC; Shields C; Ramesh VR; Tercilla O; Hagan MP
    Urol Oncol; 2007; 25(2):101-9. PubMed ID: 17349523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.
    Hellerstedt B; Pienta KJ; Redman BG; Esper P; Dunn R; Fardig J; Olson K; Smith DC
    Cancer; 2003 Oct; 98(8):1603-10. PubMed ID: 14534875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
    Algarté-Génin M; Cussenot O; Costa P
    Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.